Worth Watching: Nevro Corp Can’t Be More Risky. Trades Sigfnicicantly Lower

Worth Watching: Nevro Corp Can't Be More Risky. Trades Sigfnicicantly Lower

The stock of Nevro Corp (NYSE:NVRO) is a huge mover today! About 2.38M shares traded hands or 380.03% up from the average. Nevro Corp (NYSE:NVRO) has risen 39.91% since April 6, 2016 and is uptrending. It has outperformed by 37.95% the S&P500.
The move comes after 8 months negative chart setup for the $2.38 billion company. It was reported on Nov, 8 by Barchart.com. We have $76.92 PT which if reached, will make NYSE:NVRO worth $166.60M less.

Analysts await Nevro Corp (NYSE:NVRO) to report earnings on November, 14. They expect $-0.39 earnings per share, up 44.29% or $0.31 from last year’s $-0.7 per share. After $-0.27 actual earnings per share reported by Nevro Corp for the previous quarter, Wall Street now forecasts 44.44% negative EPS growth.

Nevro Corp (NYSE:NVRO) Ratings Coverage

Out of 9 analysts covering Nevro Corp (NYSE:NVRO), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Nevro Corp has been the topic of 12 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm earned “Market Outperform” rating on Tuesday, August 9 by JMP Securities. The firm has “Market Perform” rating given on Tuesday, March 29 by Northland Capital. The stock of Nevro Corp (NYSE:NVRO) has “Overweight” rating given on Friday, July 22 by Piperjaffray. The stock of Nevro Corp (NYSE:NVRO) has “Overweight” rating given on Tuesday, August 9 by JP Morgan. The firm has “Outperform” rating given on Friday, September 25 by BMO Capital Markets. The firm earned “Overweight” rating on Friday, July 22 by PiperJaffray. The stock of Nevro Corp (NYSE:NVRO) earned “Outperform” rating by William Blair on Tuesday, July 19.

According to Zacks Investment Research, “Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California.”

More news for Nevro Corp (NYSE:NVRO) were recently published by: Reuters.com, which released: “BRIEF-Nevro Corp reports qtrly loss per share of $0.14” on November 07, 2016. Fool.com‘s article titled: “Why Nevro Corp. Is Up Big Today” and published on August 09, 2016 is yet another important article.

NVRO Company Profile

Nevro Corp., incorporated on October 4, 2006, is a medical device company. The Firm has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment